C. Saura Manich

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

LBA15 Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer

C. Saura Manich, Joyce O’Shaughnessy, Philippe Aftimos et al. · Annals of Oncology · 2021 · 104 citations

Medicine, Oncology, Pharmacology +15

LBA20 A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2− primary breast cancer (BC)

Sherene Loi, Giuseppe Curigliano, Roberto Salgado et al. · Annals of Oncology · 2023 · 103 citations · Full text

Medicine, Oncology, Pharmacology +17

279P Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)

C. Saura Manich, Shanu Modi, Ian E. Krop et al. · Annals of Oncology · 2021 · 32 citations

Medicine, Oncology, Pharmacology +16

Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09.

Sara M. Tolaney, Zefei Jiang, Qingyuan Zhang et al. · Journal of Clinical Oncology · 2025 · 30 citations

Medicine, Oncology, Pharmacology +17